Aortic Stenosis is the most common valvular heart disease in developed countries. Over the past decade, Transcatheter Aortic Valve Implantation (TAVI) has become increasingly popular thanks to its low invasiveness. However, one of the primary side effects is the release of debris from the native calcified valve while positioning the prosthesis, which may cause cerebrovascular events (CVEs). Because of the risks associated to CVEs, several approaches have been developed to try to reduce this issue, such as the use of cerebral protection devices (CPDs), able to capture and/or deflect particles, impeding their passage in the supra-aortic vessels. In this thesis work, an experimental set-up for the in vitro testing of commercial CPD was developed.